R
Rimas V. Lukas
Researcher at Northwestern University
Publications - 198
Citations - 3749
Rimas V. Lukas is an academic researcher from Northwestern University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 160 publications receiving 2386 citations. Previous affiliations of Rimas V. Lukas include University of Chicago.
Papers
More filters
Journal ArticleDOI
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Junfei Zhao,Andrew X. Chen,Robyn D. Gartrell,Andrew M. Silverman,Luis Aparicio,Tim Chu,Darius Bordbar,David Shan,Jorge Samanamud,Aayushi Mahajan,Ioan Filip,Rose Orenbuch,Morgan Goetz,Jonathan T. Yamaguchi,Michael Cloney,Craig Horbinski,Rimas V. Lukas,Jeffrey Raizer,Ali I Rae,Jinzhou Yuan,Peter Canoll,Jeffrey N. Bruce,Yvonne M. Saenger,Peter A. Sims,Fabio M. Iwamoto,Adam M. Sonabend,Raul Rabadan +26 more
TL;DR: This study shows that clinical response to anti-PD-1 immunotherapy in GBM is associated with specific molecular alterations, immune expression signatures, and immune infiltration that reflect the tumor’s clonal evolution during treatment.
Journal ArticleDOI
An overview of meningiomas.
Robin A. Buerki,Craig Horbinski,Tim J. Kruser,Peleg M. Horowitz,Charles David James,Rimas V. Lukas +5 more
TL;DR: This review will cover the histo- and molecular pathology of meningiomas, including recent 2016 updates to the WHO classification of CNS tumors, and discuss clinical and radiographic presentation and therapeutic management.
Journal ArticleDOI
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
TL;DR: The role of EGFR and related molecular pathways in the genesis of the normal CNS and their relationship to glial tumorigenesis are reviewed and barriers to effective treatment as they relate to anatomic specialization of the CNS are discussed.
Journal ArticleDOI
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.
E. Antonio Chiocca,E. Antonio Chiocca,John S. Yu,Rimas V. Lukas,Rimas V. Lukas,Isaac H. Solomon,Keith L. Ligon,Hiroshi Nakashima,Daniel Triggs,David A. Reardon,Patrick Y. Wen,Brittany M. Stopa,Ajay Naik,Jeremy Rudnick,Jethro Hu,Priya Kumthekar,Bakhtiar Yamini,Jill Buck,Nathan Demars,John A. Barrett,Arnold Gelb,John Zhou,Francois Lebel,Laurence J.N. Cooper,Laurence J.N. Cooper +24 more
TL;DR: This phase 1 trial showed acceptable tolerability of regulated hIL-12 with encouraging preliminary results, and inflammatory infiltrates in patients undergoing resection of recurrent high-grade glioma support an immunological antitumor effect of h IL-12.
Journal ArticleDOI
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Erik Ladomersky,Lijie Zhai,Alicia Lenzen,Kristen L. Lauing,Jun Qian,Denise M. Scholtens,Galina Gritsina,Xuebing Sun,Ye Liu,Fenglong Yu,Wenfeng Gong,Yong Liu,Beibei Jiang,Tristin Tang,Ricky Patel,Leonidas C. Platanias,C. David James,Roger Stupp,Rimas V. Lukas,David C. Binder,Derek A. Wainwright +20 more
TL;DR: A novel and clinically relevant immunotherapeutic approach with associated mechanistic considerations that have formed the basis of a newly initiated phase I/II trial for glioblastoma patients are highlighted.